A Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer

被引：0
|
作者：
Forero, A. [1 ]
Saleh, M. [1 ]
Galleshaw, J. [1 ]
Jones, C. [1 ]
Shah, J. [1 ]
Percent, I [1 ]
Nabell, L. [1 ]
Carpenter, J. [1 ]
Falkson, C. [1 ]
Krontiras, H. [1 ]
Urist, M. [1 ]
Bland, K. [1 ]
De Los Santos, J. [1 ]
Meredith, R. [1 ]
Caterinicchia, V [1 ]
Bernreuter, W. [1 ]
O'Malley, J. [1 ]
Li, Y. [1 ]
LoBuglio, A. [1 ]
机构：
[1] Univ Alabama, Birmingham, AL USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：567S / 567S
页数：1
相关论文
共 50 条
  • [41] Decreased estrogen receptor and progesterone receptor expression associated with neoadjuvant therapy of exemestane in combination with celecoxib in postmenopausal women with breast cancer
    deHart, J. R.
    Jimenez, R. E.
    Shapiro, C. L.
    Povoski, S. P.
    LABORATORY INVESTIGATION, 2007, 87 : 28A - 28A
  • [42] Decreased estrogen receptor and progesterone receptor expression associated with neoadjuvant therapy of exemestane in combination with celecoxib in postmenopausal women with breast cancer
    deHart, J. R.
    Jimenez, R. E.
    Shapiro, C. L.
    Povoski, S. P.
    MODERN PATHOLOGY, 2007, 20 : 28A - 28A
  • [43] AMEERA-4, a phase 2 window study of SAR439859 vs letrozole in post-menopausal women with newly diagnosed estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) breast cancer
    Campone, Mario
    Herold, Christina
    Wang, Qiuyan
    Pelekanou, Vasiliki
    Cartot-Cotton, Sylvaine
    Ling, Bethany
    CANCER RESEARCH, 2021, 81 (04)
  • [44] Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
    Jisun Kim
    Woosung Lim
    Eun-Kyu Kim
    Min-Kyoon Kim
    Nam-Sun Paik
    Sang-Seol Jeong
    Jung-han Yoon
    Chan Heun Park
    Sei Hyun Ahn
    Lee Su Kim
    Sehwan Han
    Seok Jin Nam
    Han-Sung Kang
    Seung Il Kim
    Young Bum Yoo
    Joon Jeong
    Tae Hyun Kim
    Taewoo Kang
    Sung-Won Kim
    Yongsik Jung
    Jeong Eon Lee
    Ku Sang Kim
    Jong-Han Yu
    Byung Joo Chae
    So-Youn Jung
    Eunyoung Kang
    Su Yun Choi
    Hyeong-Gon Moon
    Dong-Young Noh
    Wonshik Han
    BMC Cancer, 14
  • [45] Randomized pre-operative study of 750 mg of fulvestrant and 20 mg tamoxifen in premenopausal women with estrogen receptor-positive breast cancer
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 150 - 151
  • [46] Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
    Kim, Jisun
    Lim, Woosung
    Kim, Eun-Kyu
    Kim, Min-Kyoon
    Paik, Nam-Sun
    Jeong, Sang-Seol
    Yoon, Jung-han
    Park, Chan Heun
    Ahn, Sei Hyun
    Kim, Lee Su
    Han, Sehwan
    Nam, Seok Jin
    Kang, Han-Sung
    Kim, Seung Il
    Yoo, Young Bum
    Jeong, Joon
    Kim, Tae Hyun
    Kang, Taewoo
    Kim, Sung-Won
    Jung, Yongsik
    Lee, Jeong Eon
    Kim, Ku Sang
    Yu, Jong-Han
    Chae, Byung Joo
    Jung, So-Youn
    Kang, Eunyoung
    Choi, Su Yun
    Moon, Hyeong-Gon
    Noh, Dong-Young
    Han, Wonshik
    BMC CANCER, 2014, 14
  • [47] COST-EFFECTIVENESS ASSESSMENT FOR COLOMBIA OF LETROZOLE VS. TAMOXIFEN IN ADJUVANT TREATMENT OF HORMONE RECEPTOR-POSITIVE, POST-MENOPAUSAL EARLY BREAST CANCER WOMEN
    Gamboa, O.
    Chicaiza, L.
    Garcia, M.
    VALUE IN HEALTH, 2009, 12 (07) : A496 - A496
  • [48] Circulating oxidative stress parameters in pre- and post-menopausal healthy women and in women suffering from breast cancer treated or not with neoadjuvant chemotherapy
    Jesus Ramirez-Exposito, Maria
    Sanchez-Lopez, Estefania
    Cueto-Urena, Cristina
    Duenas, Basilio
    Carrera-Gonzalez, Pilar
    Navarro-Cecilia, Joaquin
    Dolores Mayas, Maria
    Arias de Saavedra, Jose M.
    Sanchez-Agesta, Rafael
    Martinez-Martos, Jose M.
    EXPERIMENTAL GERONTOLOGY, 2014, 58 : 34 - 42
  • [49] Anti-proliferative and molecular effects of neoadjuvant (pre-operative) gefitinib alone or in combination with anastrozole in epidermal growth factor receptor (EGFR) positive, estrogen receptor alpha [ERα) positive patients with primary breast cancer.
    Polychronis, A
    Sinnett, HD
    Hadjiminas, D
    Singhal, H
    Mansi, JL
    Ali, S
    Slade, MJ
    Shousha, S
    Morrisson, K
    Coombes, RC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 16S - 16S
  • [50] Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy
    Kasami, M.
    Uematsu, T.
    Yabuzaki, T.
    Sugimura, H.
    MODERN PATHOLOGY, 2008, 21 : 41A - 41A
12345